Morl Christopher John 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Jan 17, 2020
Insider Transaction Report
Form 4
Morl Christopher John
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2020-01-16$3.95/sh+3,011$11,893→ 3,011 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-16−3,011→ 150,344 totalExercise: $3.95Exp: 2026-10-20→ Common Stock (3,011 underlying) - Sale
Common Stock
2020-01-16$65.40/sh−3,011$196,932→ 0 total - Exercise/Conversion
Common Stock
2020-01-15$3.95/sh+12,023$47,491→ 12,023 total - Sale
Common Stock
2020-01-15$65.23/sh−12,023$784,274→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-15−12,023→ 153,355 totalExercise: $3.95Exp: 2026-10-20→ Common Stock (12,023 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.45, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.005 to $66.03, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of October 3, 2016, subject to continued service through such dates.